John Paulson Madrigal Pharmaceuticals, Inc. Transaction History
Paulson & Co. Inc.
- $1.38 Billion
- Q1 2024
A detailed history of John Paulson (Paulson & Co. Inc.) transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Paulson & Co. Inc. holds 1,775,000 shares of MDGL stock, worth $419 Million. This represents 34.28% of its overall portfolio holdings.
Number of Shares
1,775,000
Previous 1,105,741
60.53%
Holding current value
$419 Million
Previous $256 Million
85.27%
% of portfolio
34.28%
Previous 24.68%
Shares
4 transactions
Others Institutions Holding MDGL
# of Institutions
313Shares Held
20MCall Options Held
824KPut Options Held
1.04M-
Janus Henderson Group PLC London, X02.6MShares$614 Million0.39% of portfolio
-
Baker Bros. Advisors LP New York, NY1.97MShares$465 Million6.66% of portfolio
-
Avoro Capital Advisors LLC New York, NY1.94MShares$459 Million6.26% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.67MShares$394 Million0.01% of portfolio
-
Black Rock Inc. New York, NY1.21MShares$286 Million0.01% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $4.04B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...